STAT+: Karuna’s treatment for schizophrenia achieves study goals, bolsters FDA filing plans
Karuna Therapeutics said Monday that its treatment for schizophrenia reduced psychosis reported by patients — achieving the main goal of a large clinical trial and supporting similarly positive results from previously conducted studies.
The company intends to file a marketing application for its drug, called KarXT, with the Food and Drug Administration by the middle of the year. If approved, the Karuna drug would usher in the first new class of medicines for the treatment of schizophrenia in decades.
Continue to STAT+ to read the full story…
